# Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

> **NCT07149454** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Lanzhou Institute of Biological Products Co., Ltd** · enrollment: 68 (estimated)

## Conditions studied

- Tetanus

## Interventions

- **DRUG:** Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
- **DRUG:** Human Tetanus Immunoglobulin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07149454
- **Lead sponsor:** Lanzhou Institute of Biological Products Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-08-18
- **Primary completion:** 2026-05-27
- **Final completion:** 2026-06-24
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07149454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07149454, "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07149454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*